Carica papaya leaf extract (CPLE) is known to increase platelet counts (PCs) in certain infections.

To examine the effects of live and robotic cat-assisted therapies on chemotherapy-induced symptoms and happiness levels in patients with cancer.

Paclitaxel-induced peripheral neuropathy (PIPN) is a condition that persists chronically in more than 60% of affected individuals, and currently there are no proven PIPN prophylaxis. Pre-clinical data suggest the angiotensin-II-receptor blocker losartan may attenuate neuro-inflammation and nerve injury. This study was conducted to assess losartan's neuroprotective effect against PIPN in patients with breast cancer.

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm that affects otherwise healthy adults. There are few systemic treatment options, highlighting an unmet need. We report the results of part 1 of the MANEUVER trial, which aimed to evaluate the efficacy and safety of pimicotinib, a highly selective, potent, colony-stimulating factor-1 receptor inhibitor, in patients with TGCT.

Relapsed resectable osteosarcoma carries a dismal prognosis of 30% 12-month post-relapse event-free survival (PREFS-12). Surgery remains the primary therapy for metastatic pulmonary osteosarcoma with the role for adjuvant therapy still undefined. There is an urgent need for effective nontoxic adjuvant therapies to improve PREFS following complete resection of metastases. Viscum album extract (Iscador® P, Iscador AG, Arlesheim, Switzerland) is a fermented aqueous extract manufactured from the leaves, stems, and berries of the white-berried hemiparasitic plant from the European mistletoe (Viscum album L.) grown on pine trees (P = Pini). It is a promising therapeutic antineoplastic agent with preclinical and clinical evidence of benefit in osteosarcoma. This includes a pilot study showing 55% PREFS in 9 pediatric, adolescent and young adult (AYA) patients with a median follow-up of 84 months. Viscum album extract has a long history of use in Europe and a track record of safety in children which allowed for the opening of a Phase II trial in the US to test the efficacy of Viscum album extract to improve PREFS in children and AYAs with relapsed osteosarcoma. Secondary outcomes include effects on quality of life and changes in immune profiling of tumor and serum samples.

OPN-2853 (formerly PLX2853, now dubbed zavabresib) is a potent, oral inhibitor of all four members of the bromodomain and extraterminal (BET) proteins, involved in epigenetic regulation across multiple cancers. This study aimed to determine the recommended Phase 2 dose (RP2D) of OPN-2853 and collect safety, pharmacokinetic and pharmacodynamic data in adults with advanced relapsed/refractory solid tumors or non-Hodgkin lymphoma (NHL).

Health-related quality of life (HRQoL) has emerged as an important outcome following the introduction of tyrosine kinase inhibitors for metastatic gastrointestinal stromal tumors (GISTs). We report the HRQoL results from the randomized, placebo-controlled, phase III CHAPTER-GIST-301 study evaluating pimitespib as fourth-line therapy for metastatic GIST.

This study was conducted to evaluate the impact of the ONKOSIS mobile application, developed within the scope of the study, on the management of chemotherapy-related symptoms and quality of life.

Migoprotafib is a potent and selective inhibitor of Src homology-2 domain-containing phosphatase 2 (SHP2) under investigation in Phase I (PhI) trials both as monotherapy and in combination with multiple therapies for patients with metastatic solid tumors. The PhI study reported herein aimed to assess both a new tablet formulation and the impact of a high-fat meal on the pharmacokinetics (PK) of migoprotafib at the recommended Phase II dose (RP2D) of 60 mg in patients. In two distinct cohorts, patients were administered migoprotafib as a tablet or capsule formulation to assess the impact of formulation, or as a tablet under fasted or fed conditions to assess the impact of food. In an evaluation of the effect of formulation in 20 subjects, the geometric mean ratios (GMRs) [90% CI] of the tablet: capsule formulation were 101 [89.8-114], and 103 [86.2-122], for AUC0-∞ and Cmax, respectively. Consumption of a high-fat meal prior to migoprotafib administration resulted in comparable AUC0-∞ and reduced Cmax compared to fasted administration in 17 subjects, with GMRs [90% CI] of 92.2 [74.5-114], and 42.4 [30.6-58.9], for AUC0-∞ and Cmax, respectively. These findings informed subsequent dosing recommendations for migoprotafib in ongoing and future clinical studies.

No neoadjuvant treatment has been considered to be standard therapy for patients with resectable intrahepatic cholangiocarcinoma with high-risk factors for recurrence. The GOLP regimen (gemcitabine-oxaliplatin, lenvatinib, and an anti-programmed death 1 antibody) has shown promising efficacy with a manageable safety profile in advanced intrahepatic cholangiocarcinoma and biliary tract cancer.

Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.

Rezatapopt is an investigational, first-in-class, oral, selective p53 reactivator that specifically binds to Y220C-mutated p53, which stabilizes p53 in its wild-type conformation and restores its functionality.

INBRX-105, a tetravalent, PD-L1-targeted TNFRSF9 (4-1BB) agonist, demonstrated preclinical antitumor activity. This first-in-human study evaluated INBRX-105 in solid tumors.

This study assessed the impact of individualised dietary support on nutritional status, psychological well-being, and quality of life in patients with gastrointestinal (GIT) cancers undergoing chemotherapy.

Immune checkpoint inhibition (ICI) benefits only a subset of patients with metastatic triple-negative breast cancer and determinants of response remain unclear. We assembled a longitudinal cohort of 103 female patients from the phase 2 TONIC trial, with samples spanning primary tumors, pretreatment metastases and on-treatment metastases during nivolumab therapy. We profiled 37 proteins in 270 tumors using highly multiplexed imaging and developed SpaceCat, an open-source pipeline that extracts more than 800 imaging features per sample, including cell density, diversity, spatial interactions and functional marker expression. Metastatic but not primary tumors contained features predictive of outcome. Spatial metrics such as immune diversity and T cell infiltration at tumor borders were most informative, while ratios of T cells to cancer cells and PDL1 on myeloid cells were also associated with response. Multivariate models stratified patients with the highest performance on treatment (area under the curve = 0.90). Bulk RNA-seq confirmed the predictive value of on-treatment samples. These findings highlight the value of longitudinal profiling to resolve evolving tumor microenvironment dynamics driving ICI response.

Cystinosis is a multisystemic lysosomal storage disorder caused by pathogenic variants in CTNS, the gene encoding cystinosin, a lysosomal transmembrane cystine transporter. In patients with cystinosis, cystine accumulates within lysosomes in all organs. The cystine-depleting agent cysteamine delays but does not prevent disease progression.

This randomized controlled study aimed to evaluate the effect of a therapeutic play intervention on early-onset nausea, vomiting, and quality of life in children receiving chemotherapy.

Dual anti-CTLA-4/PD-1 inhibitors show efficacy in numerous malignancies. We are the first to report on the efficacy of ipilimumab-nivolumab immunotherapy in a dedicated cohort of patients with gynecologic clear cell carcinomas (CCCs), which are rare, aggressive cancers.

This study aimed to determine whether aromatherapy inhalation would reduce chemotherapy-induced nausea and vomiting (CINV) among cancer patients receiving moderate to high emetogenic chemotherapy (HEC) regimen.

Paclitaxel being an effective treatment for ovarian cancer, presents one of the most critical toxicities; peripheral neuropathy (PN), a debilitating side effect that might limit continuation of chemotherapy. Vitamin B was found to significantly improve PN and Gabapentin is debatably used in chemotherapy induced peripheral neuropathy (CIPN). The aim of this study was to assess the efficacy of vitamin B prophylaxis in reducing the severity of CIPN, particularly in diabetic patients with the need for Gabapentin as additional therapy and the potential impact on disease response. A clinical trial of 146 adult ovarian cancer patients received Paclitaxel for 18 weeks; randomly allocated into two arms: One arm received vitamin B prophylaxis before starting Paclitaxel and other received upon CIPN. Gabapentin was given upon aggravation of CIPN. This study showed a significant reduction in CIPN grade over time, with fewer patients progressed to higher grades in prophylactic versus non-prophylactic group, extended to significant improvement in CIPN in prophylactic versus non-prophylactic diabetic patients. Gabapentin was more significantly required in non-prophylactic versus prophylactic group. A significant correlation was found between dose modification due to CIPN and CA125 status. Finally, a significant difference in PFS between prophylactic and non-prophylactic group was found at the end of the study. These results reinforce the potential role of vitamin B prophylaxis in improving patient outcomes through significantly reducing CIPN severity and minimizing the risk of dose reductions, thereby contributing to better disease response. Trial registration number: NCT07191587, date of registration: 09/24/2025, retrospectively registered.